Denali is providing updated guidance on cash operating expenses for FY24 and now anticipates an increase of approximately 5%-10% compared to 2023, which is an increase from previous guidance of equal to or less than FY23 cash operating expenses. This updated guidance is associated with increased activities to support filing of a BLA in early 2025 and commercial readiness for tividenofusp alfa in MPS II, and to accelerate the development of additional therapeutic programs in Denali’s TV platform portfolio.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics reports Q3 EPS (63c), consensus (61c)
- Denali Therapeutics price target raised to $45 from $40 at Jefferies
- DNLI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Denali Therapeutics’ Oditrasertib Phase 2 Study Discontinued
- Denali Therapeutics reinstated with a Market Perform at Raymond James